Bal Pharma opened higher at ₹101.20, compared with its previous close of ₹97.71. During today's session, the stock has traded between ₹95.10 and ₹101.20, with an average traded price of ₹98.05. It is currently showing an upward intraday trend.
An investment of ₹10,000 made 5 years ago in Bal Pharma is now worth
₹ 9,430.00
resulting in a loss of
₹ 570.00 (5.70%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+1.68 (+1.72%)
Day High
₹101.20
Day Low
₹95.10
Day Open
₹101.20
Prev Close
₹97.71
Volume
12,042
Value Traded
₹0.12 Cr
1W Return
-6.93%
1M Return
-7.48%
3M Return
25.18%
6M Return
30.88%
1Y Return
19.60%
Market Cap (₹ Cr.)
158
PE Ratio
21.50
PB Ratio
1.89
Dividend Yield
1.23%
ROE
7.68%
ROCE
18.01%
Book Value (₹)
51.65
Face Value (₹)
10.00
EPS (TTM)
0.71
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-6.93%
6 Week
-
1 Month
-7.48%
3 Month
25.18%
9 Month
38.16%
Bal Pharma reconstitutes statutory committees after board changes
Statutory committees reconstituted effective October 1, 2026. Mr. Ravindra Kumar Kothari exited NRC and SRC roles. Mr. Virupakshaya Himesh inducted into NRC and SRC. Changes follow AGM approval of director designation shifts.
18 days agoBal Pharma allots 10 lakh warrants to promoter Shailesh Siroya at ₹84
Bal Pharma allotted 10 lakh convertible warrants to promoter Shailesh Siroya. Issue price set at ₹84 per warrant, aggregating to ₹8.4 crore. Initial payment of ₹2.1 crore received, representing 25% of total value. Warrants convertible into equity shares over 18-month period. Promoter stake rises from 17.24% to 20.89% upon full conversion.
1mo agoBal Pharma declares ₹1.20 per share final dividend for FY26
Bal Pharma fixes September 17, 2026 as record date for FY26 final dividend. Payout set at ₹1.20 per equity share, equivalent to 12% on face value. 39th AGM scheduled for September 24, 2026 to approve dividend and director changes. Resident individuals receiving up to ₹10,000 dividend generally exempt from TDS.
1mo agoBal Pharma sets 18-month timeline for convertible warrant proceeds
Bal Pharma clarifies an 18-month timeline for utilizing net proceeds from convertible warrants. The period starts from the date of allotment and aligns with SEBI Regulation 162. The company confirms no change in the objects of the preferential issue. Disclosure was made under Regulation 30 of SEBI LODR Regulations.
1mo agoBal Pharma Q1 Results: IEPF share transfer notice issued
Bal Pharma Limited approved its Q1FY27 standalone financial results on August 12, 2026. Concurrently, the firm warned shareholders that unclaimed dividends and shares will be transferred to the IEPF Authority by October 30, 2026, if not claimed.
2mo agoBal Pharma opens 48-hour window for shareholder feedback on warrant pricing
Bal Pharma Limited issued an intimation on July 30, 2026, providing shareholders a 48-hour period to submit comments on a corrigendum to its postal ballot notice. The corrigendum, dated July 23, 2026, revised the issue price of convertible warrants to ₹84 from ₹81, increasing the potential capital raise to ₹8.4 crore for an API plant in Karnataka. Shareholders can modify their votes via remote e-voting, which remains open until August 8, 2026.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Bal Pharma is now worth
₹ 9,430.00
resulting in a loss of
₹ 570.00 (5.70%)
Note: Past profits do not guarantee future returns.
